Kestra Private Wealth Services LLC Has $15.82 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Kestra Private Wealth Services LLC raised its position in Amgen Inc. (NASDAQ:AMGN) by 9.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 54,936 shares of the medical research company’s stock after acquiring an additional 4,635 shares during the period. Kestra Private Wealth Services LLC’s holdings in Amgen were worth $15,823,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of AMGN. OFI Invest Asset Management acquired a new position in Amgen during the third quarter worth $26,000. Briaud Financial Planning Inc bought a new position in Amgen in the 3rd quarter valued at about $26,000. BOK Financial Private Wealth Inc. acquired a new position in Amgen during the 4th quarter valued at about $29,000. Providence Capital Advisors LLC bought a new stake in Amgen during the 3rd quarter worth approximately $30,000. Finally, Planned Solutions Inc. purchased a new stake in shares of Amgen in the fourth quarter worth approximately $30,000. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on AMGN. Leerink Partnrs downgraded Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. The Goldman Sachs Group increased their target price on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $329.00 price objective on shares of Amgen in a research report on Wednesday, April 3rd. StockNews.com cut shares of Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $350.00 target price on shares of Amgen in a report on Thursday, February 1st. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and an average price target of $297.40.

Amgen Stock Performance

Shares of AMGN traded up $6.40 during trading hours on Monday, hitting $276.38. The company’s stock had a trading volume of 2,678,923 shares, compared to its average volume of 2,820,901. The company has a market cap of $148.24 billion, a price-to-earnings ratio of 22.13, a PEG ratio of 2.61 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The business has a 50 day simple moving average of $274.96 and a two-hundred day simple moving average of $281.45. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. During the same period in the previous year, the business earned $4.09 EPS. Amgen’s revenue was up 19.8% compared to the same quarter last year. On average, equities analysts expect that Amgen Inc. will post 19.43 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.26%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is presently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.